Comparison Study of Psoriasis Severity Assessment Tools

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the performance of objective psoriasis severity assessment tool compared with a subjective assessment tool for the assessment of the improvement of psoriasis after oral cyclosporine A or methotrexate treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Cyclosporine; Cyclosporins; Methotrexate

Criteria

Inclusion Criteria:

• Present with chronic plaque psoriasis based on a clinical diagnosis

• Have > 5% body surface area involvement at screening

• Are a candidate for systemic therapy

• Are male or female patients 18 years or older

• Have given written informed consent approved by the Institutional Review Board

Exclusion Criteria:

• Have predominant pattern of pustular, erythrodermic, or guttate forms of psoriasis

• Have had any of the systemic non-biologic psoriasis therapy (including neotigason, cyclosporine, and methotrexate) within 4 weeks prior to baseline

• Have had etanercept within 4 weeks prior to baseline

• Have had adalimumab and infliximab within 8 weeks prior to baseline

• Have had ustekinumab within 16 weeks prior to baseline

• Presence of significant hepatic or renal disorders

• Have uncontrolled arterial hypertension

• Are women who are lactating, breastfeeding or planning pregnancy

• Have any other condition that precludes from following and completing the protocol